Slr Investment Corp. (SLRC) Stock Price & Analysis
Slr Investment Corp. (SLRC) fell 0.88% to USD 12.46 as of September 9, 2026 at 10:12 UTC, according to Nexqual real-time market data.
SLRC last closed at USD 12.57; the session ranged USD 12.44–12.59 on volume of 321,628 shares. Market capitalization is $679.75M, with a 52-week range of USD 12.13–16.73 (NMS). Source: Nexqual, September 9, 2026 at 10:12 UTC.
Key Statistics (as of September 9, 2026 at 10:12 UTC)
| Price | USD 12.46 |
|---|---|
| Change | ▼ 0.88% (down) |
| Previous Close | USD 12.57 |
| Open | USD 12.54 |
| Day Range | USD 12.44 – 12.59 |
| 52-Week Range | USD 12.13 – 16.73 |
| Volume | 321,628 shares |
| Market Cap | $679.75M |
| Exchange | NMS |
Technical Analysis (SLRC)
Nexqual's technical model rates SLRC "SELL" based on 1 bullish and 5 bearish signals across 127 daily candles, as of September 9, 2026 at 10:12 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 40.23 (neutral) |
| vs SMA50 | Below (USD 12.8) |
| MACD | -0.08 (negative) |
Analyst Ratings (SLRC)
Wall Street analysts rate SLRC "Buy" based on 8 analysts, with a mean price target of USD 14.88 (range USD 12–18), per Nexqual as of September 9, 2026 at 10:12 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 8 |
| Mean Target | USD 14.88 |
| High Target | USD 18 |
| Low Target | USD 12 |
| Buy / Hold / Sell | 4 / 3 / 1 |
Earnings (SLRC)
| Next Earnings Date | 2026-11-03 |
|---|---|
| EPS Estimate | USD 0.33 |
| Revenue Estimate | $48.93M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD 0.33 vs est 0.33 ▼ miss |
| 2026-03-31 | USD 0.33 vs est 0.4 ▼ miss |
| 2025-12-31 | USD 0.39 vs est 0.4 ▼ miss |
| 2025-09-30 | USD 0.4 vs est 0.41 ▼ miss |
Source: Nexqual, September 9, 2026 at 10:12 UTC.
Financials & Fundamentals (SLRC)
| Total Revenue | $209.56M |
|---|---|
| Revenue Growth (YoY) | -9.40% |
| Gross Margin | +100.00% |
| Operating Margin | +70.76% |
| Profit Margin | +35.20% |
| ROE | +7.47% |
| Debt / Equity | 117.47 |
| Current Ratio | 1.09 |
| Total Cash | $422.48M |
| Total Debt | $1.15B |
| Free Cash Flow | $93.51M |
Source: Nexqual, September 9, 2026 at 10:12 UTC.
Financial Health Score (SLRC)
Nexqual rates Slr Investment Corp.'s overall financial health "Mixed" across five dimensions, as of September 9, 2026 at 10:12 UTC.
| Growth | Weak — Revenue -6% YoY (annual), declining |
|---|---|
| Profitability | Strong — Operating margin 71% |
| Balance Sheet | Mixed — $422M cash vs $1.15B debt |
| Cash Flow | Strong — FCF $94M, 43% margin |
| Efficiency | Mixed — ROE 7%, ROA 3.6% |
Ownership (SLRC)
| Insider Ownership | +2.74% |
|---|---|
| Institutional Ownership | +41.54% |
| Shares Outstanding | 54.55M |
| Short % of Float | +1.75% |
Source: Nexqual, September 9, 2026 at 10:12 UTC.
Leadership (SLRC)
Slr Investment Corp. is led by Michael Stuart Gross (age 63), Chairman, President & Co-CEO, per Nexqual as of September 9, 2026 at 10:12 UTC.
| Chairman, President & Co-CEO | Michael Stuart Gross (age 63) |
|---|---|
| Co-CEO, COO & Interested Director | Bruce John Spohler (age 64) |
| CFO & Secretary | Shiraz Y. Kajee (age 45) |
Major Backers & Investors (SLRC)
Notable institutional backers of Slr Investment Corp. include Thornburg Investment Management Inc., JPMorgan, Van Eck Associates Corporation, according to Nexqual as of September 9, 2026 at 10:12 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Thornburg Investment Management Inc. | 16.62% |
| JPMorgan | 2.29% |
| Van Eck Associates Corporation | 2.02% |
| VanEck ETF Trust-VanEck BDC Income ETF | 1.49% |
| UBS Group AG | 1.13% |
| Aristotle Capital Boston, LLC | 1.13% |
| Putnam ETF Trust-Putnam BDC Income ETF | 1.06% |
| Franklin Resources, Inc. | 1.01% |
Source: Nexqual, September 9, 2026 at 10:12 UTC.
From Slr Investment Corp.'s Latest SEC 10-K Filing (filed 2026-02-24)
Key Strengths & Strategy (as disclosed to the SEC)
- SLR Investment Corp. is a business development company specializing in secured debt (first lien unitranche and second lien), subordinated (unsecured) debt, minority equity, leveraged buyouts, acquisitions, recapitalizations, general refinancing, growth capital and strategic income-oriented control equity investments in leveraged middle market companies.
- It also invests in life sciences with focus on specialty pharmaceuticals, medical devices, biotech, health Care Providers and services; health Care technology, enabling technologies and tools.
- The fund's investments generally range between $5 million and $25million.
- The fund invests in companies with debt investments between $10 million and $50 million with revenues between $50 million and $1000 million and EBITDA between $15 million and $100 million.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| PNNT | PennantPark Investment Corporat | USD 3.66 | ▼ 2.14% |
| GBDC | Golub Capital BDC, Inc. | USD 12.78 | ▼ 1.46% |
| FDUS | Fidus Investment Corporation | USD 19.62 | ▲ 0.2% |
| TCPC | BlackRock TCP Capital Corp. | USD 4.07 | ▲ 0.25% |
| NMFC | New Mountain Finance Corporatio | USD 7.36 | ▼ 1.47% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 9, 2026 at 10:12 UTC. This page is informational and not investment advice.